Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial ⁶⁸Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade

Louise Emmett, Charlotte Yin, Megan Crumbaker, +11

Journal of Nuclear Medicine

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Louise Emmett, Megan Crumbaker, Bao Ho, +12

Clinical Genitourinary Cancer

UrologyGenitourinary CancerMedicineTreatment ResponseProspective Phase 2 +5

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu, +59

The Lancet Oncology

UrologyOverall SurvivalGenitourinary CancerMedicineCancer Management +6

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker, +36

The Lancet Oncology

UrologyGenitourinary CancerMedicinePharmacologyClinical Trials +5

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, +17

Journal of Clinical Oncology

Surgical OncologyOlaparib ResultsRadiation MedicineOncologyGenitourinary Cancer +16

¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing¹⁷⁷Lu-PSMA-I&T Therapy

Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, +16

Journal of Nuclear Medicine

The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors

Sujun Chen, Jessica Petricca, Wenbin Ye, +20

Nature Communications

PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, +16

Journal of Clinical Oncology

ImmunologyImmunoeditingHigh Psma ExpressionImmunotherapeuticsImmunotherapy +15

Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, +12

Journal of Nuclear Medicine

Oncologic ImagingBiomarker (Medicine)Radiation MedicineClinical TrialsRadiopharmaceutical Therapy +24

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

Hui‐Ming Lin, Blossom Mak, Nicole Yeung, +26

EBioMedicine